Printer Friendly Version  View printer-friendly version
<< Back
Array BioPharma Names Andrew Robbins as Senior Vice President, Commercial Operations

BOULDER, Colo.--(BUSINESS WIRE)--Jul. 24, 2012-- Array BioPharma (NASDAQ: ARRY) announced today that it has appointed Andrew Robbins to the position of Senior Vice President of Commercial Operations. The creation of this new position reflects the Company’s continued transformation towards a commercial-stage company, as several products in the Array pipeline approach pivotal trials, including its wholly owned myelodysplastic syndrome and multiple myeloma programs. In his new role, Mr. Robbins will be responsible for working with Array’s research and development teams to refine the Company’s strategy, prioritizing portfolio investments and supporting corporate collaborations with Array’s strategic partners. As Array’s products move closer to market, he will develop launch plans and build an integrated sales and marketing team.

Andrew Robbins, Senior Vice President, Commercial Operations, Array BioPharma (Photo: Business Wire)

Andrew Robbins, Senior Vice President, Commercial Operations, Array BioPharma (Photo: Business Wire)

"I am delighted that Andy has decided to join the Array team,” said Ron Squarer, Chief Executive Officer. “I am confident his commercial development expertise and strategic insight will contribute to Array’s immediate and future successes."

Mr. Robbins has extensive commercial, development and strategic leadership expertise from a 15-year career in the pharmaceutical industry, with a specific focus on oncology/hematology products. Most recently he was at Hospira, Inc. where he served as General Manager/Vice President of the U.S. Alternate Site business unit, focused on the sales of pharmaceuticals and medical devices to outpatient oncology, surgery, pain and dialysis customers. In this role, he led a team of approximately 100 employees, including a national sales force, to deliver over $400 million in annual revenue. Prior to this, he was Vice President of Corporate Development and was responsible for global branded pharmaceutical marketing and business development, research and development portfolio prioritization, global strategy and corporate venture investing. During his tenure, he designed and executed a strategy to build a late-stage hematology/oncology and acute pain pipeline via licensing and acquisition. Mr. Robbins also served on the Board of Directors for three venture-backed healthcare companies, two of which were focused on innovative hematology/oncology products.

Before Hospira, Mr. Robbins was a commercial leader within Pfizer’s oncology unit, responsible for shepherding a portfolio of 12 preclinical and clinical stage products through development using a “fast-to-patient” approach. Several of these products, including Sutent® (sunitinib), Inlyta® (axitinib) and Xalkori® (crizotinib) have been commercialized.

Mr. Robbins holds an MBA from the Kellogg School of Management, Northwestern University and a bachelor's degree from Swarthmore College.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about expectations that events will occur that will result in greater value for the Company, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate, our future plans to progress and develop our proprietary programs and the plans of our collaborators to progress and develop programs we have licensed to them and our plans to build a commercial-stage company. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on Form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially viable drugs; risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates; the ability of our collaborators and of Array BioPharma Inc. to meet objectives tied to milestones and royalties; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials within and outside the United States; our ability to achieve and maintain profitability and maintain sufficient cash resources; the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities; our ability to out-license our proprietary candidates on favorable terms; and our ability to attract and retain experienced scientists and management. We are providing this information as of July 24, 2012. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

Photos/Multimedia Gallery Available:

Source: Array BioPharma

Array BioPharma
Tricia Haugeto, 303-386-1193

ShareThis Copy and Paste